Company Arecor Therapeutics plc

Equities

AREC

GB00BMWLM973

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 16:35:28 17/07/2025 BST			5-day change	1st Jan Change
49.00 ^GBX	0.00%		+2.08%	-33.33%

07-14	Fulcrum sells Uranium stakes, Bluebird eyes Bitcoin	AN
07-14	Arecor Establishes New Scientific Advisory Board	CI

Business description: Arecor Therapeutics plc

Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.

Number of employees: 44

Sales by Activity: Arecor Therapeutics plc

Fiscal Period: December	2020	2021	2022	2023	2024
Biotechnology	1.7M	1.16M	2.4M	4.57M	5.05M

See all business segments

Geographical breakdown of sales: Arecor Therapeutics plc

Fiscal Period: December	2020	2021	2022	2023	2024
UK	-	71K	1.14M	2.89M	2.88M
Switzerland	-	-	240K	488K	618K
Germany	-	-	-	332K	598K
USA	-	940K	784K	556K	466K
The Netherlands	-	-	-	-	433K
Italy	-	-	-	274K	54K
India	-	-	135K	30K	-
Rest of World	962K	71K	-	-	-
Rest of Europe	736K	76K	108K	-	-

See all geographic segments

Executive Committee: Arecor Therapeutics plc

Manager	Title	Age	Since
Sarah Howell CEO	Chief Executive Officer	50	12/04/2021
David J. Ellam DFI	Director of Finance/CFO	-	17/11/2024
Jan Jezek CTO	Chief Tech/Sci/R&D Officer	-	31/07/2007
David Gerring PRN	Corporate Officer/Principal	-	-
Fiona Lawrence LAW	General Counsel	-	-

See ARECOR THERAPEUTICS PLC governance

Composition of the Board of Directors: Arecor Therapeutics plc

Director	Title	Age	Since
Sarah Howell BRD	Director/Board Member	50	12/04/2021
Mohammad Fazeli BRD	Director/Board Member	60	31/08/2017
Andrew Richards CHM	Chairman	65	12/04/2021
Christine Soden BRD	Director/Board Member	67	30/04/2021
Jeremy Morgan BRD	Director/Board Member	62	-

Composition of the Board of Directors

Shareholders: Arecor Therapeutics plc

Name	Equities	%	Valuation
BGF Investment Management Ltd. 9.961 %	3,760,994	9.961 %	2 M p
UNILEVER PLC 7.763 %	2,931,002	7.763 %	2 M p
Lombard Odier Asset Management (Europe) Ltd. 5.151 %	1,944,813	5.151 %	1 M p
Chelverton Asset Management Ltd. 4.37 %	1,650,000	4.37 %	983 565 p
Oxford Technology Management Ltd. 4.205 %	1,587,776	4.205 %	946 473 p

List of ARECOR THERAPEUTICS PLC shareholders

Company details: Arecor Therapeutics plc

Arecor Therapeutics Plc

Chesterford Research Park

CB10 1XL, Little Chesterford

+44 1223 426 060

http://arecor.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARECOR THERAPEUTICS PLC	0.00%	+2.08%	-48.15%	-84.69%	24.9M
LONZA GROUP AG	+0.04%	+0.11%	+11.94%	+1.32%	50.48B
BEONE MEDICINES LTD.	+3.16%	+13.54%	+87.26%	+66.55%	33.07B
CELLTRION, INC.	+2.04%	+2.44%	+4.40%	+9.85%	28.19B
IQVIA HOLDINGS INC.	+2.31%	-2.07%	-29.61%	-23.85%	27.44B
EUROFINS SCIENTIFIC SE	+0.30%	+0.03%	+25.55%	-22.67%	12.65B
ICON PUBLIC LIMITED COMPANY	+2.08%	-3.95%	-56.26%	-28.55%	11.45B
ASCENDIS PHARMA A/S	+0.88%	-0.14%	+27.19%	+106.14%	10.62B
QIAGEN N.V.	-0.61%	-1.34%	+9.63%	-2.10%	10.46B
TEMPUS AI, INC.	+1.33%	+2.00%	+52.55%	-	10.38B
Average	+1.13%	+1.27%	+8.45%	+2.44%	19.48B
Weighted average by Cap.	+1.32%	+1.74%	+17.52%	+12.91%